ISSN: 2249–9504
CAS CODEN: IJPCDX

DEPRESSION CONTROL IN BREAST CANCER PATIENTS: A NEW HPLC-UV METHOD FOR THE SIMULTANEOUS DETERMINATION OF THE CO-ADMINISTERED DRUGS, LETROZOLE AND VILAZODONE, IN HUMAN PLASMA

Abstract

Author(s): AM. El-Kosasy, MH. Abdel Rahman and SH. Abdelaal *

Upon cancer diagnosis, patients frequently suffer a painful emotional reaction that progresses to a clinical depression. Adequate depression control increases patients' compliance to therapy and improves quality of life. This work proposes a new simple sensitive high performance liquid chromatographic method with UV detection for the simultaneous determination of the frequently co-administered anti-tumor agent; Letrozole and anti-depressant; Vilazodone in Human plasma. The proposed method employs a simple liquid -liquid extraction technique. The separation was carried out in a Phenomenex® RP-C1 8 column (250 x 4.6 mm, 5 um) and the mobile phase was potassium phosphate buffer (pH= 5.5) and methanol (50:50, v/v) with gradient flow rate conditions. UV detection was carried out at 240 nm for both drugs. Calibration curves were linear over concentration ranges 70-1000 and 140-1120 ng/ml for Letrozole and Vilazodone; respectively. Validation parameters such as linearity, accuracy, precision and stability were performed in accordance to FDA Bioanalytical validation guidelines. The proposed method is sensi tive to determine the maximum plasma concentration of both drugs with adequate accuracy and precision, thus a valuable tool for further pharmacokinetic and pharmacodynamic studies.

Get the App